TY  - JOUR
TI  - Assessment of miR-1179 As a Potential Biomarker
in Juvenile Myoclonic Epilepsy
AB  - Objective: Juvenile myoclonic epilepsy (JME) is one of the most common childhood types of epilepsy and comprises 5-10% of all
epilepsies. Altered expression levels of microRNAs (miRNAs) have been reported in epilepsy as in many diseases. As is known, miRNAs
regulate gene expression post-transcriptionally and have potential as diagnostic biomarkers due to their stability in clinical samples.
Herein, this study aimed to evaluate miR-1179 levels of JME patients and assess the potential of miR-1179 as a diagnostic biomarker.
Materials and Methods: Twenty patients and 20 healthy controls were recruited in this study and total RNA was extracted from peripheral
blood samples of participants. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to calculate the relative
expression level of miR-1179. Additionally, receiver operating characteristic (ROC) curve was conducted to evaluate the diagnostic value
of miR-1179 in JME.
Results: Expression levels of miR-1179 were statistically significantly increased in patients with JME compared to healthy controls
(p<0.0001). ROC analysis revealed that miR-1179 is a well diagnostic biomarker with an area under the curve (AUC) of 0.89.
Conclusion: miR-1179 may be considered a remarkable biomarker in the diagnosis of JME. The interaction between miR-1179 and its
target Calmodulin 1 (CALM1) should be reinforced through functional studies. Further research in larger cohorts will help to enlighten the
etiopathogenesis of JME.
AU  - Ilgen Uslu, Ferda
AU  - Süsgün, Seda
AU  - Toruntay, Ceyhun
AU  - BAYRAKOĞLU, ALİŞAN
AU  - Yucesan, Emrah
DO  - 10.26650/experimed.2021.1033564
PY  - 2022
JO  - EXPERIMED
VL  - 12
IS  - 1
SN  - 2630-6050
SP  - 1
EP  - 5
DB  - TRDizin
UR  - http://search/yayin/detay/523272
ER  -